Results 41 to 50 of about 1,148,675 (153)

Pediatric Head and Neck Malignancies [PDF]

, 2022
Head and neck masses represents a common clinical entity in pediatric age group. In general, these masses are classified in to developmental, inflammatory, or neoplastic.
J Baby John, R Sowmya, Sowndarya ​ Gunasekaran, Pradeep Daniel Gainneos, D Vinola, Basil M Mathew   +5 more
core   +1 more source

Ultrasound-Propelled ferroptosis catalytic amplification for Active-targeting sonodynamic anti-tumor therapy with Concurrent Photoacoustic/MRI visualization

Ultrasonics Sonochemistry
Sonodynamic therapy (SDT) faces significant challenges in treating aggressive malignancies due to inherent apoptotic resistance. To address this, we developed a multifunctional nanoliposome designed for mitochondrial targeting and synergistic induction ...
Qiqing Chen, Lin Xie, Yangcheng Yao, Qiang Zhou, Yan Lin, Dandan Sun, Zhuole Wu, Dong Xie, Xiangxiang Jing   +8 more
doaj   +1 more source

Spectrum, Management Strategies, and Early Outcomes of Dual Primary Malignancies: A Single Tertiary-Center Experience

Introduction: The occurrence of a second primary malignancy in a patient with a known cancer is referred to as a dual primary malignancy, which may be synchronous or metachronous. The incidence of dual malignancies is increasing worldwide (2–17%).
Lithika Lavanya. M, Surabhi Chandel
core   +1 more source

Sequential Diagnosis of Metastatic Breast Cancer and Follicular Lymphoma in a Postmenopausal Woman: Navigating Endocrine and Cytotoxic Therapies in a Complex Oncologic Setting

Case Reports in Oncology
Introduction: Dual primary malignancies involving solid and hematologic tumors are rare, posing significant diagnostic and therapeutic challenges. We report here a case of concurrent breast cancer and follicular lymphoma.
Hye Sook Kim, Sunhee Chang, Jae Il Kim, Hye Ryeong Kwon   +3 more
doaj   +1 more source

Dual-mode protocol latency comparison.

, 2022
Dual-mode protocol latency comparison.
Shuyang Ren (14053541), Choonhwa Lee (2921532), Sumi Helal (2921526), Eunsam Kim (2921529)   +3 more
core   +1 more source

Optimizing pyrazine-2-carboxamide derivatives as dual FLT3/HDAC inhibitors with enhanced pharmacokinetics and immunotherapeutic potential

Acta Pharmaceutica Sinica B
Dual FLT3/HDAC inhibition represents a promising synergistic strategy to address tumor heterogeneity. Building upon our prior lead 25h, we developed novel 6-ethylpyrazine-2-carboxamide derivatives via systematic structural optimization to enhance ...
Yingjie Chang, Xue Li, Huirui Wang, Huajun Zhao, Yue Zhou, Wenchao Bi, Ruixue Cheng, Yuxin Shi, He Weng, Xinying Yang, Wei Zhao, Hao Fang, Xuben Hou   +12 more
doaj   +1 more source

Dual-Band Tunable Recursive Active Filter [PDF]

, 2011
This letter presents a novel recursive active filter topology that provides dual-band performance, with independent tuning capability in both bands. The dual-band operation is achieved by using two independent feedback lines.
García Pérez, Oscar Alberto, Aznar Ballesta, Francisco, Daniel Segovia-Vargas, Vicente Gonzalez-Posadas, Francisco Aznar-Ballesta, Segovia Vargas, Daniel, Oscar Garcia-Perez, González Posadas, Vicente   +7 more
core   +1 more source

Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers

OncoImmunology
Despite recent advances in immunotherapy against B cell malignancies such as BCMA (B cell maturation antigen) and CD19-targeted treatments using soluble T cell-engaging (TCE) antibodies or chimeric antigen receptor T cells (CAR-T), there is still an ...
Miriam Velasco-Sidro, Javier Arroyo-Ródenas, Laura Díez-Alonso, Ángel Ramírez-Fernández, Luis Álvarez-Vallina   +4 more
doaj   +1 more source

Dual citizenship as a path-dependent process [PDF]

, 2004
Faist T, Gerdes J, Rieple B. Dual citizenship as a path-dependent process. COMCAD Arbeitspapiere - working papers, 7.
Gerdes, Jürgen, Thomas Faist, Rieple, Beate, Faist, Thomas, Jürgen Gerdes, Beate Rieple   +5 more
core   +1 more source

Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies

Frontiers in Immunology
BackgroundCD19 combined with CD22 or CD20 therapy is a promising immunotherapy approach for the treatment of hematological malignancies. Dual-targeted CD19/CD22 CAR T and CD19/CD22 CAR T-cell therapy are currently being evaluated in clinical trials, and ...
Xiaoshuang Yuan, Feiqing Wang, Feiqing Wang, Peng Zhao, Bo Yang, Xu Yang, Ting Tian, Bingbing Li, Guangyang Liu, Sanbin Wang, Dongxin Tang, Zhixu He, Yanju Li, Yang Liu   +13 more
doaj   +1 more source